ARTICLE | Company News
Metasyn other research news
October 10, 1994 7:00 AM UTC
The Cambridge, Mass., company received two $75,000 Phase I SBIR grants to develop MRI agents to improve the diagnosis of breast cancer and other tissues. Both grants will support preclinical research.
A grant from the National Institutes of Diabetes and Digestive and Kidney Disease will fund development of MS-264, a liver-specific agent for use in detecting cancer that has spread to that organ. ...